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Abstract
Purpose To assess whether extracorporeal treatment (ECTR) improves outcome of patients with metformin-associated lactic
acidosis (MALA) and to evaluate the clinical applicability of the Extracorporeal Treatments in Poisoning Workgroup (EXTRIP)
criteria for starting ECTR in metformin poisoning.
Methods Patients with metformin serum concentrations above 2 mg/l who were admitted in the Deventer Teaching Hospital
between January 2000 and July 2019 and complied with the definition of MALA (pH < 7.35 and lactate concentration > 5 mmol/
l) were included. Mortality and clinical parameters of patients treated with ECTR or not were compared. In addition, treatment of
MALA in clinical practice was verified against the criteria of EXTRIP.
Results Forty-two patients were included. Lactate (13.8 versus 10.5 mmol/l, p = 0.01), creatinine (575 versus 254 umol/l,
p < 0.01)), metformin (29.4 versus 8.6 mg/l, p < 0.01) concentrations, and vasopressor requirement (72% versus 23%,
p < 0.01) were significantly higher in the ECTR-group. Blood pH (7.05 versus 7.19, p = 0.03) and bicarbonate (6 versus
11 mmol/l, p < 0.01) were significantly lower. Mortality, length of hospital stay, and mechanical ventilation requirement were
not statistically different. In 83% of patients, treatment of MALAwas in accordance with the EXTRIP criteria.
Conclusions Although there was no statistical benefit in mortality shown from ECTR, ECTR might be lifesaving in MALA,
considering the ECTR-group was significantly sicker than the non-ECTR-group.
The majority of patients were treated in line with the EXTRIP criteria. Severity of lactic acidosis and renal impairment were
the main indications for initiating ECTR.
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Introduction
Metformin is the most commonly prescribed oral antidia-
betic drug in non-insulin-dependent type 2 diabetes
mellitus (NIDDM). Metformin inhibits gluconeogenesis,
facilitates cellular glucose uptake, and decreases insulin
resistance [1]. Metformin treatment is associated with a
lower incidence of cardiovascular events and mortality in
NIDDM [2]. Although metformin is considered to be a safe
and well tolerated drug, its use may rarely be complicated
by lactic acidosis [1, 3–6]. The most widely accepted
mechanism how metformin causes hyperlactatemia and
metabolic acidosis is by partial inhibition of oxidative
phosphorylation complex 1 of the mitochondrial electron
transport chain. Another possible mechanism in which
metformin may elevate plasma lactate levels is through
inhibition of pyruvate carboxylase which results in both
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accelerated lactate production and reduced lactate metabo-
lism [1, 3–5]. There appears to be a clear relationship be-
tween metformin accumulation and lactic acidosis, al-
though some authors have pointed out that several such
patients had other confounding risk factors for lactic aci-
dosis [3–5, 7].
Metformin-associated lactic acidosis (MALA) is a seri-
ous adverse event with a high mortality rate of up to 50%
[1, 4]. The incidence of MALA varies from 0 to 138 per
100.000 patient years and may increase in the coming
years due to the increase in the number of type 2 diabetes
mellitus patients and the use of metformin [4, 6, 8, 9].
Several studies suggest that starting timely treatment might
reduce MALA-related morbidity and mortality [8–14].
Extracorporeal treatments (ECTRs) may be necessary to
remove metformin, clear lactate, and correct acid-base ab-
normalities [1, 11]. Calello et al. [1] formulated specific
recommendations for starting ECTR in metformin poison-
ing based on a systematic l i terature search: the
Extracorporeal Treatments in Poisoning Workgroup
(EXTRIP) criteria [15], which have been included in the
treatment guidelines for metformin intoxication by the
Dutch Poisons Information Centre (DPIC) [16]. However,
the evidence levels of the EXTRIP criteria are low and
their validity in clinical practice has not been assessed
yet. We therefore evaluated the treatment of MALA pa-
tients in clinical practice. The aim of this study was firstly
to assess whether ECTR improves outcome of MALA pa-
tients. Secondly, we aimed to evaluate whether the
EXTRIP criteria for starting ECTR in MALA are applica-
ble in clinical practice, i.e., to what extent patients who
received ECTR and those who did not fulfill the EXTRIP
criteria for starting ECTR [1].
Methods
A retrospective single-center cohort study was conducted
at the Deventer Teaching Hospital in the Netherlands.
Laboratory data were searched for patients who had their
metformin serum concentrations measured between
January 2000 and July 2019. In these patients, serum met-
formin concentration measurement had been requested be-
cause of a clinical suspicion of MALA, based on docu-
mented metformin use and concurrent illness leading to
an emergency department visit. In the Deventer Teaching
Hospital, the metformin assay is routinely available 24 h a
day. Results are available for clinical decisions within 4 h.
Patients were included if they met the MALA definition:
pH < 7.35 and lactate > 5.0 mmol/l in association with met-
formin exposure [1]. Only patients with serum metformin
concentrations above the lower limit of quantification of
our analysis method, i.e., 2 mg/l, were included. The
following patient data were extracted from the medical
records: age, gender, admission diagnosis, ECTR treatment
(or not), reasons for initiating ECTR (or not), decreased
consciousness, vasopressor requirement, mechanical ven-
tilation requirement, length of hospital stay, mortality (de-
fined as in-hospital mortality), and laboratory results on
admission: serum concentrations of creatinine, lactate, bi-
carbonate and metformin, and blood pH. In the Deventer
Teaching Hospital, ECTR is readily and unrestrictedly
available for treatment of MALA patients.
Patients were divided into an ECTR and non-ECTR
group, and the concentrations of lactate, creatinine, bicar-
bonate and metformin, blood pH, decreased consciousness,
vasopressor and mechanical ventilation requirement,
length of hospital stay, and mortality were compared. In
case of normal distribution of continuous data, the inde-
pendent sample t test was used. The non-parametric Mann-
Whitney test was used for not normally distributed and
ordinal data. The Chi square test was used to compare
nominal data between groups. In all tests, a p value <
0.05 was considered statistically significant. Data analysis
was performed with SPSS version 24.0.
In the ECTR and non-ECTR group, we assessed whether
patients met the EXTRIP criteria for starting ECTR depicted
in Table 1. Impaired kidney function is defined by the
EXTRIP nephrology sub-committee as (1) advanced stage
G3b, G4, or G5 chronic kidney disease (i.e., eGFR < 45 mL/
min/1.73 m2), (2) kidney disease: Improving Global
Outcomes (KDIGO) stage 2 or 3 acute kidney injuries, (3) in
the absence of a baseline serum creatinine, 176 μmol/L in
adults and 132 μmol/L in elderly/low muscle mass patients,
and (4) the presence of oligo/anuria regardless of serum cre-
atinine concentration.
In those patients who were not treated according to the
EXTRIP criteria, the reasons for initiating ECTR or not were
evaluated.
Table 1 EXTRIP criteria for starting ECTR in metformin poisoning [1]
Indications
ECTR is recommended if:
• Lactate concentration greater than 20 mmol/l
• Blood pH less than or equal to 7.0
• Standard therapy (supportive measures, bicarbonate, etc.) fails
ECTR is suggested if:
• Lactate concentration is 15–20 mmol/l
• Blood pH 7.0–7.1
Comorbid conditions that lower the threshold for initiating ECTR:
• Impaired kidney function
• Shock
• Decreased level of consciousness
• Liver failure
EXTRIP Extracorporeal Treatments in Poisoning Workgroup
ECTR Extracorporeal treatment
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Results
In our hospital pharmacy laboratory database, we identified
160 patients who had serum metformin concentrations mea-
sured. Of these, 42 patients met the inclusion criteria of
MALA and were included in the study. Forty patients (95%)
had renal impairment on admission and 29 patients (69%)
were treated with ECTR. ECTR was conducted in the inten-
sive care unit. ECTR modalities used were continuous veno
venous hemofiltration (CVVH) (19 patients), hemodialysis
(HD) (7 patients), or a sequential combination of CVVH and
HD (3 patients). The patient characteristics and the results of
the comparison between the ECTR and non-ECTR groups are
listed in Table 2. The main admission diagnoses were dehy-
dration, sepsis, shock, and myocardial infarction. Detailed in-
formation of the patient characteristics per patient is given in
Online Resource 1 (ECTR-group) and Online Resource 2
(non-ECTR-group).
Thirty-five of the 42 (83%) patients were treated in line
with the EXTRIP criteria.
Of the 29 patients in the ECTR-group, 28 (97%) fulfilled the
EXTRIP criteria to receive ECTR. Clinical reasons for starting
ECTR in these patients were severe metabolic acidosis, renal
failure, hyperkalaemia, and high metformin concentrations.
Ninety-seven percent of the ECTR group met the criterion of
impaired renal function of Calello et al. [1] in which the thresh-
old for initiating ECTR could be lowered. One patient (patient
no. 27, Online Resource 1) did not fulfill the EXTRIP criteria.
This patient was admitted because of an intentional overdose
and did not meet the criterion of impaired renal function of
Calello et al. [1]. ECTRwas started because of the combination
high serummetformin concentration and lactic acidosis in order
to eliminate metformin and to correct the acidosis.
Of the 13 patients in the non-ECTR group, in 7 (54%) of
the patients treatment, (non-ECTR) was in line with the
EXTRIP criteria. One patient (patient no. 6, Online Resource
2) did not fulfill the EXTRIP criteria for starting ECTR, and in
6 patients, ECTR was not necessary because they recovered
after starting supportive care.
For the other 6 (46%) patients, ECTR should have been
considered according to the EXTRIP criteria. Supportive care
was started in these patients but they died shortly after the start
of the treatment. Four patients died within 1 day from cardiac
arrest. In one patient, a conservative policy was started be-
cause of the very bad prognosis due to comorbidity and she
died 1 day after admittance. One patient (patient no.10,
Online Resource 2) did not recover with supportive care and
died 1 month after admission probably from sepsis. There
were no data available in this patients’medical record whether
ECTR was considered.
Discussion
This retrospective cohort study shows a lower but not statisti-
cally different mortality in MALA patients treated with ECTR
compared to those who were not. The overall mortality of
40% in our study is in line with the mortality reported in
previous studies, ranging from 20 to 50% [7, 8, 12–14,
17–21]. Blood pH, lactate, creatinine, and serum metformin
concentration in the ECTR group in this study are similar to
that reported in the literature [9, 13, 20–22]. The significantly
higher lactate and creatinine concentrations in the ECTR
group compared to the non-ECTR group have also been re-
ported in other studies [9, 12, 19].
Table 2 Results: patient characteristics and comparison clinical parameters ECTR versus non-ECTR group
Patient characteristics ECTR N = 29
Mean ± sd (range)
Non-ECTR N = 13
Mean ± sd (range)
Statistical analysis
Gender 6 M 23 F 5 M 8 F
Age (years) 71 ± 9 (52–87) 77 ± 11 (58–89)
pH 7.05 ± 0.18 (6.61–7.34) 7.19 ± 0.18 (6.85–7.33) p = 0.027
Lactate (mmol/l) 13.8 ± 4.9 (5.8–23.2) 10.5 ± 2.8 (6.7–18) p = 0.033
Bicarbonate (mmol/l) 6 ± 3 (2–13) 11 ± 4 (2–17) p < 0.01
Metformin concentration (mg/l) 29.4 ± 20.3 (2.3–100) 8.6 ± 11.2 (2.2–37) p < 0.01
Creatinine (umol/l) 575 ± 268 (113–1039) 254 ± 192 (70–720) p < 0.01
Decreased consciousness N (%) 9 (31%) 3 (23%) p = 0.699
Vassopressor requirement N (%) 21 (72%) 3 (23%) p < 0.01
Mechanical ventilation requirement N (%) 6 (21%) 1 (8%) p = 0.296
Length of stay (days) 17.3 ± 23.6 (2–120) 7.8 ± 9.0 (1–32) p = 0.067
Mortality N (%) 11 (38%) 6 (46%) p = 0.616
ECTR Extracorporeal Treatment
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Patients in the ECTR group were sicker than patients in the
non-ECTR group considering the degree of lactic acidosis, kid-
ney function, and vasopressor requirement while having a low-
er but not statistically different, mortality. As hyperlactatemia in
general and in MALA patients is associated with increased
mortality [8, 11, 23–25], this at least comparable outcome sug-
gests there might be a benefit for ECTR. This is also suggested
by Peters et al. [19]. Our study was probably underpowered to
show a statistical difference. We also compared the length of
hospital stay (17.3 versus 7.8 days, p = 0.067), but in this study,
this parameter is less suitable as outcome measure compared to
mortality because of the large range in the ECTR group (2–
120 days) and the high percentage patients who died within 1–
2 days in the non-ECTR group.
To evaluate whether the EXTRIP criteria for initiating
ECTR in patients with MALA are applicable in clinical prac-
tice, we compared the indications for starting ECTR in this
study with the recommendations of Calello et al. [1]. Overall,
83% of our patients were treated in line with the EXTRIP
criteria. In the ECTR group, 97% and in the non-ECTR group
54% of the patients fulfilled the EXTRIP criteria. Severity of
lactic acidosis and kidney function were the main indications
for initiating ECTR in this study. This is also shown in the
EXTRIP criteria [1] and the study of Corcia et al. [9].
Moreover, in accordance with Corchia et al. [9], we identified
hyperkalaemia as a reason for starting ECTR. In contrast,
hemodynamic instability and shock, as proposed by Corcia
et al. [9] and EXTRIP [1, 15] for initiating ECTR, were not
recorded in the patients’medical records in this study. Calello
et al. [1] have not formulated a threshold for metformin serum
concentration because at the time of formulation of these rec-
ommendations, there was much uncertainty regarding the val-
ue of metformin concentrations in relation to the prognosis
and the limited availability of the metformin assays. Some
studies have shown a correlation between metformin concen-
tration and mortality [8, 9, 20] while others have not [17, 21,
25, 26]. Despite the uncertainty concerning its prognostic val-
ue, measuring metformin serum concentrations could be of
diagnostic value in MALA and may assist in its management
[9, 22, 26]. However, establishing a specific threshold for
metformin serum concentrations is not possible based on the
results of this study.
The EXTRIP criteria include lowering thresholds of pH
and lactate for initiating ECTR in impaired kidney function,
shock, decreased level of consciousness, and liver failure but
this is not quantified. The majority of the ECTR group in this
study had impaired renal function, and the mean pH and lac-
tate concentration were 7.05 and 13.8 mmol/l respectively. In
clinical practice, comorbidity is common, and it is not always
clear whether there is metformin accumulation, showing the
heterogeneity regarding the EXTRIP criteria and real-life sce-
narios. Because of this heterogeneity, formulating more con-
cise criteria for initiating ECTR in MALA patients is very
difficult. The main reasons for not initiating ECTR in this
study were recovery after starting supportive care or death
shortly after admission. Six patients who met the EXTRIP
criteria were not treated with ECTR and died. At the time of
admission of these patients, the EXTRIP criteria were not
implemented in our hospital. Four out of these six patients
died within 1 day from cardiac arrest and there was no renal
indication for starting ECTR. Additionally, in the non-ECTR
group, 54% of patients had serum metformin concentrations
lower than 5 mg/l which is in line with the ‘normal’ value of
serum metformin concentrations in therapeutic use [4, 27].
Therefore, it is debatable whether metformin was the cause
of MALA in these patients. Lalau et al. [4] suggested adding
serummetformin concentration higher than 5 mg/l as criterion
to MALA to distinguish it from metformin unrelated lactic
acidosis (MULA). However, we used the definition of
MALA pH< 7.35 and lactate >5 mmol/l in association with
metformin exposure as formulated by Calello et al. [1] be-
cause we wanted to evaluate Calello’s recommendations in
clinical practice. In addition, we validated metformin expo-
sure by only including patients with verifiable serum metfor-
min concentrations to avoid discussion about metformin
exposure.
The present study is one of the largest cohort studies re-
garding the management of MALA. The strength of our study
is that metformin concentrations, lactate, blood pH, and kid-
ney function were measured simultaneously on admission and
during subsequent treatment. Furthermore, only patients with
verified metformin serum concentrations were included.
Lalau et al. [4] presented the lack of these combined data as
major methodological flaw in most studies on MALA.
However, we did not measure metformin concentrations in
erythrocytes, which probably better reflects metformin tissue
effects, and we have no information on last intake so we can-
not refer to peak versus trough concentrations [4]. A limitation
of our study is that other causes of lactic acidosis were not
ruled out which could have influenced the mortality in this
study. Other limitations include the retrospective and
monocentric design and selection bias. We selected patients
based on serum metformin concentration measurement.
MALA patients without serum metformin concentration mea-
surement could have been missed. Finally, as presented in the
EXTRIP guidelines, metformin and lactate clearance are low-
er with continuous renal replacement therapy (CRRT) than
with intermittent HD. As such, the predominant use of
CVVH in our study might have weakened the results in favor
for ECTR.
For clinical practice, we recommend that clinicians be
alert to MALA in the emergency department when pa-
tients are admitted with lactic acidosis in combination
with metformin use. ECTR might be lifesaving in the
treatment of MALA and should therefore be considered
at an early stage. The EXTRIP-criteria are a good starting
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point for the decision to start ECTR but each individual
patient needs to be evaluated separately. Severity of lactic
acidosis and renal impairment are the main indications for
initiating ECTR. Knowledge of the metformin concentra-
tions may be a valuable additional parameter for the di-
agnosis and management of MALA. Therefore, we rec-
ommend implementing metformin assays as routine inves-
tigation with 24-h availability in hospitals treating MALA
patients.
Conclusion
Although there was no statistical difference in mortality be-
tween the treatment with or without ECTR, ECTR might be
lifesaving in treating MALA. Patients in the ECTR group
were sicker compared to the non-ECTR group considering
the degree of lactic acidosis, kidney function, and vasopressor
requirement and had at least a comparable mortality. In 83%
of the patients, treatment was in line with the EXTRIP criteria.
Severity of lactic acidosis and renal impairment were the main
indications for initiating ECTR. Measuring serum metformin
concentrations may assist in the diagnosis and management of
MALA.
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